Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 29.12
- Piotroski Score 4.00
- Grade Buy
- Symbol (PRAX)
- Company Praxis Precision Medicines, Inc.
- Price $64.89
- Changes Percentage (-2.13%)
- Change -$1.41
- Day Low $62.24
- Day High $67.50
- Year High $67.93
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $146.50
- High Stock Price Target $170.00
- Low Stock Price Target $120.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$10.95
- Trailing P/E Ratio -3.7
- Forward P/E Ratio -3.7
- P/E Growth -3.7
- Net Income $-123,277,000
Income Statement
Quarterly
Annual
Latest News of PRAX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Praxis Tech maximises PIX approval ratios in Brazil with new cascading feature
Praxis Tech introduces PIX Cascading feature to boost payment success rates in Brazil. The technology aims to enhance transaction approvals by providing a seamless process for merchants connected to t...
By Yahoo! Finance | 1 day ago -
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
Praxis Precision Medicines Inc. announced positive results from its Phase 2 study on relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathy patients, showing a 46% reduction in mot...
By Yahoo! Finance | 1 month ago -
TotalEnergies to divest interests in UK's West of Shetland gas fields to the Prax Group
TotalEnergies finalized the sale of its West of Shetland assets to the Prax Group, including gas fields and the Shetland Gas Plant. The deal involves the transfer of employees and aligns with TotalEne...
By Yahoo! Finance | 3 months ago
